Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals

Novartis

Pfizer

Regeneron Pharmaceuticals

Here's one genetics play that you might want to put on your radar.

This Genetics Stock Could Have a Bright Future

Etsy

Monster Beverage

Nokia

Epizyme

Fate Therapeutics

Ionis Pharma

With the trading day about halfway over, markets pushed higher into the weekend. The Nasdaq was the biggest winner on the day, with the index up over 1.3%.

Etsy, Monster Beverage, Nokia and More Friday Afternoon Analyst Calls

Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2021 Results - Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -4.55% and -23.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the first quarter ended March 31, 2021.

Intellia Therapeutics Announces First Quarter 2021 Financial Results

Editas Medicine

Roblox

Teva Pharmaceutical

United States Steel

Albertsons Companies

Crown Castle International

Domino's Pizza

With the trading day more than halfway over, the broad markets were getting crushed.

Domino's, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls

Intellia has optimized its core LNP technology to work across multiple targets within the liver.

Intellia Expands Its In Vivo Advantage

Beam Therapeutics

Intel

Gene therapies could be poised to enter an era of extraordinarily rapid advancement.

3 Exciting Biotech Stocks to Buy Right Now

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Intellia Therapeutics, Inc. (NTLA) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T.

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates

- Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD)

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting

CRISPR Therapeutics

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the company's Board of Directors.

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

Cellectis SA

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) has increased by 10.61%. This is why it happened.

NTLA Stock Price Increased 10.61%: Why It Happened

CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the European Commission (EC) has granted orphan drug designation to NTLA-2001. This investigational medicinal product is being developed as a treatment for transthyretin amyloidosis (ATTR), a rare condition that can impact a number of organs and tissues within the body through the accumulation of misfolded transthyretin (TTR) protein deposits. NTLA-2001 is the first experimental CRISPR therapy – a Nobel Prize-winning technology – to be administered systemically via intravenous dosing to edit a gene, specifically the TTR gene, that encodes the production of TTR protein, inside the human body. In addition to being the first therapy of its kind, it also has the potential to be the first curative treatment and it may be able to halt and reverse ATTR progression.

Intellia Therapeutics' Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting on Nucleic Acid Therapies. The data shows how the Company's proprietary base editors can expand its genome editing capabilities by enabling the introduction of multiple gene knockouts simultaneously with no detectable increase in translocation above background levels. The meeting is being held virtually from March 24-26, 2021.

Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors

The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days, while it is up 6% over the last ten trading days. We believe the stock, despite the recent rally, may continue to.

What's Next For Intellia Therapeutics Stock After A 15% Rise In A Week?

bluebird bio

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today appeared first on InvestorPlace.

Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today

- Demonstrates the promise of Intellia's proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell disease

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

Our indicative theme of Gene Editing stocks is down by about 24% year-to-date, compared to the S&P 500 which has remained almost flat over the same period. The recent sell-off comes on the back of rising bond yields, which have caused investors to rotate out of technology and other growth stocks.

Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?

Intellia reached clinical trials in early November 2020. The company will release initial data from NTLA-2001 sometime in the next several months.

Intellia Therapeutics Is At A Pivotal Moment

Intellia (NTLA) miss earnings and revenues estimates in the fourth quarter of 2020. Stock up.

Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4

Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q4 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2020.

News for Intellia Therapeutics Stock (NTLA)